We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+2.67%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$770M
AUM Growth
-$93.1M
Cap. Flow
-$86.4M
Cap. Flow %
-11.23%
Top 10 Hldgs %
76.77%
Holding
47
New
8
Increased
7
Reduced
11
Closed
2

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$36.6M
2
PTCT icon
PTC Therapeutics
PTCT
+$8.85M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$8.77M
4
EW icon
Edwards Lifesciences
EW
+$2.87M
5
BNTX icon
BioNTech
BNTX
+$2.32M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$28.3M
2
RVNC
Revance Therapeutics, Inc.
RVNC
+$18.1M
3
INSM icon
Insmed
INSM
+$14.6M
4
BIIB icon
Biogen
BIIB
+$12.6M
5
STAA icon
STAAR Surgical
STAA
+$10.8M

Sector Composition

Rank Sector Weight
1 Healthcare 98.76%
2 Financials 1.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VERV
26
DELISTED
Verve Therapeutics
VERV
$2.79M 0.36%
575,817
– –
EW icon
27
Edwards Lifesciences
EW
$53.6B
$2.6M 0.34%
+39,473
New +$2.87M
MIRM icon
28
Mirum Pharmaceuticals
MIRM
$6.04B
$2.52M 0.33%
64,700
– –
RLMD icon
29
Relmada Therapeutics
RLMD
$503M
$2.37M 0.31%
732,400
– –
NUVB icon
30
Nuvation Bio
NUVB
$2.25B
$1.77M 0.23%
772,652
– –
TSHA icon
31
Taysha Gene Therapies
TSHA
$2.05B
$1.63M 0.21%
811,268
– –
TVTX icon
32
Travere Therapeutics
TVTX
$5.86B
$1.55M 0.2%
110,719
– –
STOK icon
33
Stoke Therapeutics
STOK
$2.13B
$1.55M 0.2%
125,861
– –
BCYC
34
Bicycle Therapeutics
BCYC
$284M
$1.35M 0.18%
+59,582
New +$1.37M
HUM icon
35
Humana
HUM
$46.7B
$1.26M 0.16%
3,985
– –
ALDX icon
36
Aldeyra Therapeutics
ALDX
$91.7M
$1.22M 0.16%
225,465
– –
YARW
37
Yarrow Bioscience, Inc. Common Stock
YARW
$114M
$837K 0.11%
8,909
– –
ELEV
38
DELISTED
Elevation Oncology
ELEV
$779K 0.1%
1,298,097
-502,009
-28% -$744K
TIL icon
39
Instil Bio
TIL
$50.7M
$752K 0.1%
+11,165
New +$263K
ACRS icon
40
Aclaris Therapeutics
ACRS
$860M
$655K 0.09%
569,832
– –
PYXS icon
41
Pyxis Oncology
PYXS
$201M
$624K 0.08%
+170,000
New +$595K
GBIO
42
DELISTED
Generation Bio
GBIO
$372K 0.05%
15,048
– –
BLUE
43
DELISTED
bluebird bio
BLUE
$314K 0.04%
30,213
-201,455
-87% -$3.35M
URGN icon
44
UroGen Pharma
URGN
$2.39B
$311K 0.04%
24,500
– –
ABEO icon
45
Abeona Therapeutics
ABEO
$425M
$81.3K 0.01%
+12,865
New +$67.2K
CYTK icon
46
Cytokinetics
CYTK
$10.5B
– –
-111,717
Closed -$6.05M
1
2

Similar funds

AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
PCM
Primavera Capital Management George Town, Cayman Islands $648M AUM 6.1% 1-Year Est. Return
HCM
Huber Capital Management El Segundo, California $647M AUM 24.91% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Palo Alto Investors's Q3 2024 Portfolio in Review

As of Q3 2024, Palo Alto Investors held 47 positions worth $770M, down 11% from $863M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Palo Alto Investors withdrew a net $86.4M in Q3 2024, closing 2 positions and reducing 11 holdings. Its most notable exit was Cytokinetics, an estimated $6.05M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 94% a quarter earlier, followed by Financials.

Against the trend, Palo Alto Investors opened a new position in Alnylam Pharmaceuticals worth $38.7M.

  • Palo Alto Investors's largest Q3 2024 buy was Alnylam Pharmaceuticals: 140,681 shares worth $38.7M.
  • Palo Alto Investors added most to Iovance Biotherapeutics in Q3 2024, an estimated $8.77M increase.
  • Palo Alto Investors's biggest Q3 2024 reduction was United Therapeutics, cutting an estimated $28.3M.
  • Palo Alto Investors fully exited Cytokinetics in Q3 2024, selling an estimated $6.05M.
  • Palo Alto Investors's ten largest holdings make up 77% of its $770M portfolio in Q3 2024.
  • Palo Alto Investors opened 8 new positions and closed 2 in Q3 2024.
  • Palo Alto Investors's portfolio value fell 11% quarter-over-quarter to $770M.

Based on Palo Alto Investors's 13F filing for Q3 2024, filed 14 Nov 2024.